Elevated expression of TRiC/CCT subunits in multiple cancers correlates with tumor progression, while depletion suppresses tumor growth, metastasis, and chemoresistance,[24, 25, 26] highlighting the need to systematically investigate the TRiC/CCT oncogenic mechanisms to reveal novel therapeutic vulnerabilities. The gene discussed is FLVCR2; the disease is cancer.